Genmab — Maj 2013
-
Enig - Roche er ikke nogen man bare kører hen over. Det bliver en krig. Problemet for Genmab er at rituximab er godkendt omend det sikkert er dårligere end ofatumumab, men så længe Ibrutinib ikke er godkendt, så er det altså sin sag at lave kombinationer af to ikke godkendte stoffer !!
-
jeg synes det vigtigste, og som vi egentligt kun fik på ProInvestor, var at btd fremskynder milestones
-
det bliver en meget meget vigtigt værdidriver i de næste år. Der kan regner ubeskriveligt mange kontanter ned til os
-
jeg tror ikke kun at milestones kommer ved data
-
Jansen ? Mener du J&J ?
-
The combination of HDMP and ofatumumab is an effective, tolerable, non-myelosuppressive treatment regimen. We observed a higher ORR and longer PFS than those previously reported with single agent mAb. This regimen may be useful for patients who are unable to tolerate more aggressive, myelosuppressive therapies, or have not responded to other treatments.
-
@gen.co vi var nok nogen der ikke havde troet dette for et år siden endsige et halvt. Din ding ding
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind